LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Advanced Solid Tumors
Interventions
DRUG

Panobinostat (LBH589), Carboplatin and Paclitaxel

"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."

Trial Locations (3)

1011

Mèdecin Adjoint, ME - CePO, CHUV, Lausanne

4031

Huniversitätsspitals Basel, Basel

6500

Istituto Oncologico della Svizzera Italiana, Bellinzona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Southern Europe New Drug Organization

OTHER

NCT01159418 - LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter